Denosumab-induced hypocalcaemia in metastatic castrate-resistant prostate cancer
Denosumab is a fully human MAB that acts as a potent anti-resorptive by inhibiting activation of osteoclasts by inhibiting the receptor activator of nuclear factor-kappa B (RANK) ligand. Hypocalcaemia has been reported as one of the serious adverse sequelae of use of denosumab. We present a case of...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bioscientifica
2019-12-01
|
| Series: | Endocrinology, Diabetes & Metabolism Case Reports |
| Online Access: | https://doi.org/10.1530/EDM-19-0063 |